Rhea-AI Summary
Hancock Jaffe Laboratories (HJLI) has announced the enrollment of the first two patients for its first-in-human CoreoGraft study, aimed at providing a safer alternative for coronary artery bypass grafting (CABG) using their innovative conduits. This trial, conducted at the Italian Hospital Asuncion in Paraguay, will eventually include up to five patients. Initial findings from animal studies indicate promising results, including high graft patency rates. HJLI estimates the U.S. market potential for the CoreoGraft at over $2 billion annually due to the high failure rates of traditional grafts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.39%
Tags